Levetiracetam
Product Images NDC 24689-106

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 24689-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apnar Pharma Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Clcr Calculation (Clcr Calculation)

Clcr Calculation (Clcr Calculation)
A text panel showing formulas for calculating creatinine clearance (CLcr). It includes the equation adjusting for age, weight, and serum creatinine, with a factor for female patients, and an adjustment for body surface area (BSA). The formulas provide step-by-step calculation instructions.*
FDA Label Image

Figure 1- Responder Rate In Study 1 (Figure 1 Responder Rate In Study 1)

Figure 1- Responder Rate In Study 1 (Figure 1 Responder Rate In Study 1)
A bar graph titled 'Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1' showing the percentage of patients achieving this response. The x-axis compares placebo and two dose groups of Levetiracetam (1000 mg/day and 3000 mg/day). The y-axis indicates the percentage of patients, ranging from 0% to 45%. Bars show 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with significant differences noted versus placebo.*
FDA Label Image

Figure 2- Responder Rate In Study 2-period A (Figure 2 Responder Rate In Study 2 Period A)

Figure 2- Responder Rate In Study 2-period A (Figure 2 Responder Rate In Study 2 Period A)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing percentages of patients responding to placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The percentages are approximately 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with statistical significance indicated for the levetiracetam groups versus placebo.*
FDA Label Image

Figure 3- Responder Rate In Study 3 (Figure 3 Responder Rate In Study 3)

Figure 3- Responder Rate In Study 3 (Figure 3 Responder Rate In Study 3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing placebo and Levetiracetam 3000 mg/day groups. The vertical axis represents the percentage of patients, with placebo at 14.4% and Levetiracetam at 39.4%, marked statistically significant versus placebo.*
FDA Label Image

Figure 4- Responder Rate In Study 4 (Figure 4 Responder Rate In Study 4)

Figure 4- Responder Rate In Study 4 (Figure 4 Responder Rate In Study 4)
A bar chart titled 'Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing percentage of patients between placebo (N=97) and Levetiracetam (N=101). The placebo group shows a responder rate of 19.6%, while the Levetiracetam group shows 44.6%, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 5- Responder Rate For All Patients Ages In Study 5 (Figure 5 Responder Rate For All Patients Ages In Study 5)

Figure 5- Responder Rate For All Patients Ages In Study 5 (Figure 5 Responder Rate For All Patients Ages In Study 5)
A bar graph showing the responder rate for patients aged 1 month to under 4 years achieving at least a 50% reduction from baseline in Study 5. The graph compares Levetiracetam (N=58) with a responder rate of 43.1% to Placebo (N=51) with a responder rate of 19.6%, indicating a statistically significant difference versus placebo.*
FDA Label Image

Figure 6- Responder Rate In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6 Responder Rate In Pgtc Seizure Frequency Per Week In Study 7)

Figure 6- Responder Rate In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6 Responder Rate In Pgtc Seizure Frequency Per Week In Study 7)
A bar graph comparing responder rates showing percentage reduction of seizure frequency per week in Study 7. The left bar represents placebo with about 45.2% of patients, and the right bar represents levetiracetam with about 72.2% of patients. The levetiracetam bar is marked as statistically significant compared to placebo.*
FDA Label Image

Levetiracetam Oral Solution_ Label (Levetiracetam Oral Solution Label)

Levetiracetam Oral Solution_ Label (Levetiracetam Oral Solution Label)
Label for Levetiracetam Oral Solution USP 100 mg/mL by Apnar Pharma LP. It displays dosage form, strength, 473 mL volume, NDC 24689-106-01, and pharmacist instructions along with storage and warning details. The label includes the company logo and the product's packaging guidance.*
FDA Label Image

Levetiracetam_ Structure (Levetiracetam Structure)

Levetiracetam_ Structure (Levetiracetam Structure)
Chemical structure of levetiracetam showcasing its molecular arrangement with a pyrrolidone ring and various attached functional groups.*
FDA Label Image

Total Daily Dose For Pediatric Patient (Total Daily Dose For Pediatric Patient)

Total Daily Dose For Pediatric Patient (Total Daily Dose For Pediatric Patient)
A text panel showing a formula for calculating total daily dose (mL/day) based on daily dose in mg/kg/day, patient weight in kg, and a concentration of 100 mg/mL. This calculation appears related to dosing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.